{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:07:10Z","timestamp":1776942430647,"version":"3.51.4"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Janssen Pharmaceutica NV"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0218071","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T17:36:52Z","timestamp":1560447412000},"page":"e0218071","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5012-287X","authenticated-orcid":true,"given":"P.","family":"Tak\u00e1cs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Czobor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Feh\u00e9r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gimesi-Orsz\u00e1gh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Fadgyas-Freyler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bacskai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Rakonczai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Borsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hegyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"N\u00e9meth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Sermon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Bitter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,6,13]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/schbul\/sbs150","article-title":"Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials","volume":"40","author":"T Kishimoto","year":"2014","journal-title":"Schizophr Bull"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/YIC.0000000000000249","article-title":"Long-acting injectable second-generation antipsychotics in first-episode psychosis: a narrative review","volume":"34","author":"M Salgueiro","year":"2019","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.9758\/cpn.2018.16.4.361","article-title":"Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis","volume":"16","author":"SC Park","year":"2018","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/eb-2014-101803","article-title":"Relapse with oral antipsychotics versus long-acting injectable antipsychotics: new paradoxical findings","volume":"17","author":"TH Jobe","year":"2014","journal-title":"Evid Based Ment Health"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development","volume":"29","author":"T Stroup","year":"2003","journal-title":"Schizophr Bull"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S2215-0366(18)30090-7","article-title":"Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial","volume":"5","author":"CLM Hui","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/JCP.0000000000000959","article-title":"Clinical Characteristics of Patients With Schizophrenia Who Successfully Discontinued Antipsychotics: A Literature Review","volume":"38","author":"H Tani","year":"2018","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/schbul\/sbx176","article-title":"Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up","volume":"44","author":"H Taipale","year":"2018","journal-title":"Schizophr Bull"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/YIC.0000000000000082","article-title":"Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs","volume":"30","author":"CA Bossie","year":"2015","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/schbul\/sbu128","article-title":"Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study","volume":"41","author":"J Nielsen","year":"2015","journal-title":"Schizophr Bull"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","article-title":"A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia","volume":"168","author":"J Tiihonen","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12888-017-1507-8","article-title":"Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations","volume":"17","author":"JP Anderson","year":"2017","journal-title":"BMC Psychiatry"},{"issue":"9","key":"ref13","first-page":"754","article-title":"Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge","volume":"21","author":"SC Marcus","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"ref14","doi-asserted-by":"crossref","first-page":"e0179049","DOI":"10.1371\/journal.pone.0179049","article-title":"Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study","volume":"12","author":"F Decuypere","year":"2017","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2017.10.030","article-title":"Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis","volume":"195","author":"M Bowtell","year":"2018","journal-title":"Schizophr Res"},{"key":"ref16","unstructured":"NEAK\u2014Nemzeti Eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si Alapkezel\u0151. or National Health Fund Administration\u2013 <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.neak.hu\" xlink:type=\"simple\">www.neak.hu<\/ext-link>"},{"key":"ref17","unstructured":"Act LXIII.\/ 2012. on re-use of public data <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/njt.hu\/cgi_bin\/njt_doc.cgi?docid=148883.295522\" xlink:type=\"simple\">http:\/\/njt.hu\/cgi_bin\/njt_doc.cgi?docid=148883.295522<\/ext-link>"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.euroneuro.2013.02.003","article-title":"Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary","volume":"23","author":"I Bitter","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"12","key":"ref19","first-page":"1259","article-title":"Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015 Apr;72(4):334\u201341","volume":"72","author":"ER Walker","year":"2015","journal-title":"Erratum in: JAMA Psychiatry"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.eurpsy.2017.05.022","article-title":"Mortality and the relationship of somatic comorbidities to mortality in schizophrenia. A nationwide matched-cohort study","volume":"45","author":"I Bitter","year":"2017","journal-title":"Eur Psychiatry"},{"key":"ref21","article-title":"Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia","author":"H Taipale","year":"2017","journal-title":"Schizophr Res"},{"issue":"2","key":"ref22","first-page":"528","article-title":"Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull. 2015 May;41(3):656\u201363","volume":"42","author":"M Torniainen","year":"2016","journal-title":"Erratum in: Schizophr Bull"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/JCP.0000000000000140","article-title":"Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia","volume":"34","author":"HC Detke","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.eurpsy.2016.05.008","article-title":"LAI versus oral: A case-control study on subjective experience of antipsychotic maintenance treatment","volume":"37","author":"F Pietrini","year":"2016","journal-title":"Eur Psychiatry"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.eurpsy.2018.06.002","article-title":"Changes in attitude towards LAI antipsychotic maintenance treatment: A two-year follow-up study","volume":"53","author":"F Pietrini","year":"2018","journal-title":"Eur Psychiatry"},{"key":"ref26","unstructured":"Summary of Product Characteristics (SMPC) of Risperdal Consta <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/risperdal-consta\" xlink:type=\"simple\">https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/risperdal-consta<\/ext-link>\u2014Last access: 2019 Mar 20"},{"issue":"19","key":"ref27","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"RB D\u2019Agostino","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"PR Rosenbaum","year":"1983","journal-title":"Biometrika"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13561-018-0215-5","article-title":"Hospitalization rates and resource utilization of schizophrenic patients switched from oral antipsychotics to aripiprazole-depot in Germany","volume":"8","author":"C Potempa","year":"2018","journal-title":"Health Econ Rev"},{"issue":"7","key":"ref30","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3109\/15622975.2010.505663","article-title":"Patients\u2019 preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study","volume":"11","author":"I Bitter","year":"2010","journal-title":"World J Biol Psychiatry"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0218071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:42:32Z","timestamp":1609893752000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0218071"}},"subtitle":[],"editor":[{"given":"Vincenzo","family":"De Luca","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,6,13]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0218071","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,13]]}}}